Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noemi R Simon

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
European Journal of Internal Medicine|July 5, 2021
Comment to: Non-specific clinical presentations are not prognostic and do not anticipate hospital length of stay or resource utilizationRoland Bingisser, Noemi R Simon, Christian H Nickel
Swiss Medical Weekly|November 9, 2021
Disparities in emergency department access, resource allocation, and outcomes between migrants and the local populationAndrea S Jauslin, Leandra Schultze, Daniel Knuchel, et al.
Praxis|December 12, 2024
[Fever in adults]Noemi R Simon, Yaël Hofmann, Katia Boggian, et al.
Swiss Medical Weekly|December 7, 2021
Mimics and chameleons of COVID-19: patient presentation and accuracy of triage during the first waveAndrea S Jauslin, Noemi R Simon, Nina L Giudici, et al.
Journal of Clinical Medicine|July 2, 2021
Association of Frailty with Adverse Outcomes in Patients with Suspected COVID-19 InfectionNoemi R Simon, Andrea S Jauslin, Marco Rueegg, et al.
Journal of Clinical Medicine|July 2, 2021
Direct Comparison of Clinical Characteristics, Outcomes, and Risk Prediction in Patients with COVID-19 and Controls-A Prospective Cohort StudyMaurin Lampart, Marco Rüegg, Andrea S Jauslin, et al.
The Lancet. Haematology|July 2, 2022
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trialStefano Barco, Davide Voci, Ulrike Held, et al.
Thrombosis Research|November 17, 2022
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trialDavide Voci, Andrea Götschi, Ulrike Held, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
European Journal of Internal Medicine|July 5, 2021
Comment to: Non-specific clinical presentations are not prognostic and do not anticipate hospital length of stay or resource utilizationRoland Bingisser, Noemi R Simon, Christian H Nickel
Swiss Medical Weekly|November 9, 2021
Disparities in emergency department access, resource allocation, and outcomes between migrants and the local populationAndrea S Jauslin, Leandra Schultze, Daniel Knuchel, et al.
Praxis|December 12, 2024
[Fever in adults]Noemi R Simon, Yaël Hofmann, Katia Boggian, et al.
Swiss Medical Weekly|December 7, 2021
Mimics and chameleons of COVID-19: patient presentation and accuracy of triage during the first waveAndrea S Jauslin, Noemi R Simon, Nina L Giudici, et al.
Journal of Clinical Medicine|July 2, 2021
Association of Frailty with Adverse Outcomes in Patients with Suspected COVID-19 InfectionNoemi R Simon, Andrea S Jauslin, Marco Rueegg, et al.
Journal of Clinical Medicine|July 2, 2021
Direct Comparison of Clinical Characteristics, Outcomes, and Risk Prediction in Patients with COVID-19 and Controls-A Prospective Cohort StudyMaurin Lampart, Marco Rüegg, Andrea S Jauslin, et al.
The Lancet. Haematology|July 2, 2022
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trialStefano Barco, Davide Voci, Ulrike Held, et al.
Thrombosis Research|November 17, 2022
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trialDavide Voci, Andrea Götschi, Ulrike Held, et al.
Pageof 1